cisplatin + cyclophosphamide + epirubicine + fluorouracil + vindesine

This is a combination chemotherapy regimen consisting of five cytotoxic agents: - Cisplatin, a platinum-based DNA crosslinker that induces apoptosis by forming DNA adducts and inhibiting DNA synthesis and repair. - Cyclophosphamide, an alkylating agent that interferes with DNA replication and transcription through cross-linking of DNA strands. - Epirubicine (epirubicin), an anthracycline antibiotic that intercalates into DNA, inhibits topoisomerase II, and generates free radicals leading to cytotoxicity. - Fluorouracil (5-FU), a pyrimidine analog antimetabolite that inhibits thymidylate synthase, disrupting RNA and DNA synthesis. - Vindesine, a vinca alkaloid that binds to tubulin and inhibits microtubule assembly during mitosis. This combination is not standard or widely referenced in the literature as a named regimen but represents an intensive multi-agent protocol. Each component has established use in various solid tumors—most notably breast cancer—but this exact five-drug combination is not commonly described as a single regimen. The mechanism of action involves multiple pathways targeting cell division, nucleic acid synthesis, and mitotic spindle formation. Such combinations are typically used for aggressive or refractory cancers where multi-modal cytotoxicity is desired.